GlobeNewsWire · MLYS · November 8, 2026

Mineralys Therapeutics Presents New Late-Breaking Data from Transform-HTN Open-Label Extension Trial of Lorundrostat in Hypertension at AHA Scientific Sessions 2026

Get the app for more

Explore stock news, insights and company research.